Chronic kidney disease (CKD) is the deterioration of renal function over time. The main causes are diabetes and high blood pressure, which can damage the kidneys. Early stages may be asymptomatic, but later stages can cause fatigue, edema, and other issues as kidney function declines. Diagnosis involves testing kidney function and imaging tests. While CKD has no cure, treatment focuses on controlling blood pressure and diabetes, following a kidney-friendly diet, and dialysis or transplant for end-stage renal disease.
This document provides an overview of investigating heart failure patients. It discusses evaluating a clinical vignette of a heart failure patient and outlines the objectives, outline, epidemiology, etiology, classification, pathophysiology, clinical features, specific and non-specific investigations, diagnosis, and treatment of heart failure. It summarizes the findings and management of the clinical vignette case, and provides details on specific heart failure investigations including electrocardiography, chest x-ray, and echocardiography.
This document provides clinical practice guidelines for the diagnosis, evaluation, and treatment of acute kidney injury (AKI). It was developed by an international work group using a systematic review of the evidence and outlines recommendations for:
1. Defining and classifying AKI according to increases in serum creatinine and decreases in urine output.
2. Evaluating patients at risk for AKI and implementing general management strategies.
3. Preventing AKI through hemodynamic monitoring, glycemic control, and minimizing nephrotoxic medications.
4. Treating established AKI through renal replacement therapy, including criteria for initiation and discontinuation as well as specific modalities and procedures.
DKD is a leading cause of ESRD in the US, affecting 30-40% of those with diabetes. Poor glycemic control and hypertension are major risk factors for developing and progressing DKD. Clinical trials have shown that intensive control of blood glucose and blood pressure can delay and prevent kidney disease. New drugs targeting the kidney are showing promise in reducing albuminuria and slowing kidney function decline in DKD patients.
Hypertension is very common in patients with chronic kidney disease (CKD), affecting 67-92% of patients. Control of hypertension is important for slowing the loss of kidney function and reducing the risk of further kidney damage. The document discusses several risk factors for hypertension in CKD patients including older age, African descent, overweight or obesity, and concurrent diabetes or heart disease. It also reviews guidelines for treating hypertension in CKD, which generally recommend a target blood pressure under 140/90 mmHg and use of renin-angiotensin system blocking agents along with monitoring of kidney function and potassium levels.
The document is a clinical practice guideline for acute kidney injury (AKI) published by Kidney Disease: Improving Global Outcomes (KDIGO) in 2012. It contains recommendations on defining and classifying AKI, evaluating patients at risk, preventing AKI, treating AKI with renal replacement therapy, and managing specific causes of AKI like contrast-induced nephropathy. The guideline includes sections on introduction and methodology, definition of AKI, prevention and general treatment of AKI, contrast-induced AKI, and dialysis interventions. It provides tables summarizing recommendation statements and clinical practice recommendations supported by evidence reviews.
This document discusses the role of glyptins (DPP-4 inhibitors) in the management of type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). It notes that T2DM is a leading cause of CKD globally and that strict glycemic control is important for treating diabetic nephropathy. However, patients with CKD are at higher risk of hypoglycemia from antidiabetic medications. The document examines whether glyptins may be renoprotective and safer to use in CKD patients compared to other drugs due to their low risk of hypoglycemia. It reviews studies on the use of sitagliptin and other glyptins in T2
This document provides an overview of investigating heart failure patients. It discusses evaluating a clinical vignette of a heart failure patient and outlines the objectives, outline, epidemiology, etiology, classification, pathophysiology, clinical features, specific and non-specific investigations, diagnosis, and treatment of heart failure. It summarizes the findings and management of the clinical vignette case, and provides details on specific heart failure investigations including electrocardiography, chest x-ray, and echocardiography.
This document provides clinical practice guidelines for the diagnosis, evaluation, and treatment of acute kidney injury (AKI). It was developed by an international work group using a systematic review of the evidence and outlines recommendations for:
1. Defining and classifying AKI according to increases in serum creatinine and decreases in urine output.
2. Evaluating patients at risk for AKI and implementing general management strategies.
3. Preventing AKI through hemodynamic monitoring, glycemic control, and minimizing nephrotoxic medications.
4. Treating established AKI through renal replacement therapy, including criteria for initiation and discontinuation as well as specific modalities and procedures.
DKD is a leading cause of ESRD in the US, affecting 30-40% of those with diabetes. Poor glycemic control and hypertension are major risk factors for developing and progressing DKD. Clinical trials have shown that intensive control of blood glucose and blood pressure can delay and prevent kidney disease. New drugs targeting the kidney are showing promise in reducing albuminuria and slowing kidney function decline in DKD patients.
Hypertension is very common in patients with chronic kidney disease (CKD), affecting 67-92% of patients. Control of hypertension is important for slowing the loss of kidney function and reducing the risk of further kidney damage. The document discusses several risk factors for hypertension in CKD patients including older age, African descent, overweight or obesity, and concurrent diabetes or heart disease. It also reviews guidelines for treating hypertension in CKD, which generally recommend a target blood pressure under 140/90 mmHg and use of renin-angiotensin system blocking agents along with monitoring of kidney function and potassium levels.
The document is a clinical practice guideline for acute kidney injury (AKI) published by Kidney Disease: Improving Global Outcomes (KDIGO) in 2012. It contains recommendations on defining and classifying AKI, evaluating patients at risk, preventing AKI, treating AKI with renal replacement therapy, and managing specific causes of AKI like contrast-induced nephropathy. The guideline includes sections on introduction and methodology, definition of AKI, prevention and general treatment of AKI, contrast-induced AKI, and dialysis interventions. It provides tables summarizing recommendation statements and clinical practice recommendations supported by evidence reviews.
This document discusses the role of glyptins (DPP-4 inhibitors) in the management of type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). It notes that T2DM is a leading cause of CKD globally and that strict glycemic control is important for treating diabetic nephropathy. However, patients with CKD are at higher risk of hypoglycemia from antidiabetic medications. The document examines whether glyptins may be renoprotective and safer to use in CKD patients compared to other drugs due to their low risk of hypoglycemia. It reviews studies on the use of sitagliptin and other glyptins in T2
The Cardiology Group at the Health Research Institute studies new therapeutic targets for heart failure based on diet compounds and local fat development. The group has expertise culturing three human cardiovascular cell types and uses animal models to test nutraceuticals, chemicals, and diet compounds' effects on cardiovascular metabolism. Led by Dr. José Ramón González Juanatey, the group publishes in high impact journals and seeks collaboration on organized projects related to functional foods, nutraceuticals, and diet therapies.
This document discusses cardiorenal syndrome (CRS), which is characterized by concurrent heart and kidney dysfunction. It defines five types of CRS based on whether heart or kidney dysfunction occurs first and the duration. The patient case involves a 55-year-old woman presenting with chest pain, shortness of breath, and leg swelling. Her labs show stage IV chronic kidney disease and elevated BNP. She likely has type 1 acute CRS, where acute heart failure led to acute kidney injury exacerbated by fluid overload.
Cardiorenal syndromes describe disorders where dysfunction in the heart and kidneys negatively impact one another. There are 5 subtypes based on etiology and chronicity. Type 1 involves acute kidney injury secondary to heart failure. Type 2 is chronic cardiac dysfunction causing chronic kidney disease. Type 3 is acute worsening of kidney function inducing heart issues. Type 4 is primary chronic kidney disease contributing to cardiac complications. Type 5 involves systemic conditions affecting both organs. Managing cardiorenal syndromes focuses on decongestion through diuresis while preventing worsening of renal function with neurohormonal blockade.
Acute kidney injury from diagnosis to prevention and treatment strategiesLeonardo Rodrigues
- Acute kidney injury (AKI) is characterized by a rapid decline in kidney function and is associated with increased short and long-term mortality. AKI diagnosis relies on changes in serum creatinine and urine output.
- Risk factors for AKI include older age, chronic kidney disease, comorbidities like diabetes and heart disease, as well as exposures to sepsis, surgery, nephrotoxins and shock. Causes of AKI include pre-renal, intrinsic renal and post-renal factors.
- Prevention strategies focus on identifying at-risk patients, optimizing volume status, and discontinuing or avoiding nephrotoxins. Treatment involves correcting hypovolemia, discontinuing
John B. Buse, MD, PhD; David Cherney, MD, PhD, FRCP(C); and Mikhail Kosiborod, MD, FACC, FAHA, prepared useful Practice Aids pertaining to SGLT2 inhibitors for this CME activity titled “Complex Cases in Contemporary Practice: Applying New Evidence for SGLT2 Inhibitors in the Management of Patients With Comorbid Cardiometabolic Diseases.” For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at https://bit.ly/3dFKZhs. CME credit will be available until July 22, 2021.
Guidelines for use of anticoagulant in ckd with atrial fibrillationNilesh Jadhav
1. Atrial fibrillation (AF) and chronic kidney disease (CKD) are bidirectionally linked, as CKD increases the risk of AF while AF increases the risk of CKD progression.
2. Patients with CKD and AF have an increased risk of stroke and thromboembolic events. They also exhibit a paradoxical increase in bleeding risk, especially those with severe CKD.
3. Non-vitamin K antagonist oral anticoagulants (NOACs) are preferred over warfarin for stroke prevention in patients with CKD and AF, as NOACs have more predictable anticoagulant effects than warfarin and are not associated with complications in CKD patients
A 33-year-old male smoker presented with abdominal pain, fatigue, nausea and dark urine. Laboratory tests showed acute kidney injury with a creatinine of 12.2 mg/dl. Abdominal ultrasound found enlarged kidneys with increased echogenicity. He was treated conservatively but his kidney function declined further. A renal biopsy was planned but his condition dramatically improved with corticosteroid treatment, suggesting acute interstitial nephritis.
UF vs diuretics in treatment of ADHF, Cardiorenal syndrome Mohamed E. Elrggal
1. Fluid overload and congestion are major characteristics of heart failure (HF) that are important treatment targets. Diuretics have limitations like resistance and worsening renal function.
2. Ultrafiltration (UF) theoretically has advantages over diuretics for acute decompensated heart failure (ADHF) by allowing faster fluid removal without electrolyte issues.
3. However, clinical trials have had conflicting results. The UNLOAD trial found greater benefits with UF, while the CARESS-HF trial found increased renal dysfunction and adverse events with UF.
4. Further research is needed to determine optimal patient selection, monitoring of plasma refill rate during UF, and long-term outcomes comparison
World Kidney Day was established to raise awareness of chronic kidney disease (CKD) and encourage detection and prevention programs. CKD affects over 20 million Americans and is a major cause of death worldwide. While kidney failure requiring dialysis has increased, CKD is often preventable or treatable through control of diabetes, hypertension, and obesity. World Kidney Day aims to educate the public and healthcare professionals about CKD risks and signs through collaborative events around the world each March.
1. Cardio-renal syndrome (CRS) describes conditions where acute or chronic dysfunction in one organ induces acute or chronic dysfunction in the other organ.
2. Management of CRS is challenging and involves diuretics, ACE inhibitors, beta blockers, and dialysis. However, treatment outcomes remain poor, with high mortality and rates of rehospitalization.
3. While advances have been made, CRS continues to significantly impact morbidity and mortality. Early multidisciplinary management may help improve outcomes, but effective new therapies are still needed to better treat and prevent this challenging condition.
This document summarizes the five types of cardiorenal syndromes (CRS). Type 1 is acute or chronic heart failure leading to kidney dysfunction. Type 2 is chronic kidney disease contributing to heart disease. Type 3 is acute kidney injury causing acute cardiac injury or dysfunction. Type 4 is chronic kidney disease causing chronic cardiac damage. Type 5 occurs when a systemic condition like sepsis or cirrhosis affects both the heart and kidneys. The document discusses the pathogenesis, risk factors, diagnosis and treatment approaches for each type of CRS.
This document discusses relative blood volume (RBV) monitoring and its potential applications in dialysis. It provides an overview of RBV monitoring principles, compartmental fluid shifts, and RBV profiles in relation to intradialytic hypotension. While RBV monitoring shows promise for fluid management and blood pressure control, evidence from studies is mixed. The largest study to date found RBV monitoring increased mortality and hospitalizations. Further research is still needed to fully understand the clinical utility and appropriate applications of RBV monitoring.
The document discusses renal failure and its relationship to cardiovascular disease. It provides statistics on the prevalence, incidence, and mortality rates of renal failure in the US and Australia. It then covers topics such as the structure and function of the kidneys, classification of renal failure, its effects on the cardiovascular system, and approaches to treatment including dialysis, transplantation, and their risks.
a-comprehensive-approach-to-kidney-disease-and-hypertension by HazwanMohd Hanafi
This document discusses kidney disease and hypertension. It begins by outlining the key functions of the kidneys, including regulating blood pressure through the renin-angiotensin-aldosterone system. It then examines the causes and classifications of acute and chronic kidney disease. Chronic kidney disease is a growing problem due to its asymptomatic nature in early stages. The document reviews factors that can damage the kidneys and lead to reduced glomerular filtration rate. It also discusses how chronic kidney disease and reduced kidney function are linked to increased risk of cardiovascular disease, anemia, and bone disease like renal osteodystrophy. Hypertension is both a common cause and complication of chronic kidney disease. Tight blood pressure control is important to slow
This document discusses anemia in patients with heart failure and kidney disease (cardiorenal anemia). It notes that anemia is common in these patients and associated with higher mortality and costs. The pathophysiology of cardiorenal disease and anemia are both multifactorial, involving interactions between cardiac function, renal dysfunction, inflammation, and other factors. The document outlines five subtypes of cardiorenal syndrome based on whether heart or kidney dysfunction is acute or chronic. It emphasizes that a multidisciplinary approach is needed to manage cardiorenal anemia given its complex causes.
Perioperative care of patients with kidney diseases prof (1). ahmed rabeeFarragBahbah
This document discusses perioperative care of patients with kidney disease. It covers preoperative assessment and investigations, renal risk assessment, surgical risks in chronic kidney disease (CKD) patients, and preventing acute kidney injury. Key points include performing a comprehensive evaluation of CKD patients' medical history and comorbidities; adjusting dosages of renally excreted drugs; optimizing fluid, electrolyte and acid-base balance; considering preoperative dialysis for volume overloaded patients; and involving nephrologists in care of transplant recipients. Emergent surgery and advanced CKD carry higher surgical risks. The goal is to identify and address risks to avoid worsening of renal function in the perioperative period.
The document discusses chronic kidney disease (CKD), including its definition, stages, diagnosis, prevalence, costs, and treatment options such as renal replacement therapy. CKD is common and often occurs alongside other conditions like cardiovascular disease or diabetes. While usually asymptomatic, CKD can be detected through simple tests and treating it can prevent progression and complications. However, it often goes unrecognized until later stages.
This document provides an overview of chronic kidney disease (CKD). It defines CKD as kidney damage or decreased kidney function lasting at least 3 months. The global prevalence of CKD is estimated to be 13.4% with higher rates in certain regions like eastern Uganda. Common causes include diabetes, hypertension, and glomerulonephritis. Later stages of CKD can cause complications like fluid overload, hyperkalemia, and metabolic acidosis which require management approaches like dietary modifications and medications. The document discusses evaluating and managing CKD and its associated risks and complications.
The Cardiology Group at the Health Research Institute studies new therapeutic targets for heart failure based on diet compounds and local fat development. The group has expertise culturing three human cardiovascular cell types and uses animal models to test nutraceuticals, chemicals, and diet compounds' effects on cardiovascular metabolism. Led by Dr. José Ramón González Juanatey, the group publishes in high impact journals and seeks collaboration on organized projects related to functional foods, nutraceuticals, and diet therapies.
This document discusses cardiorenal syndrome (CRS), which is characterized by concurrent heart and kidney dysfunction. It defines five types of CRS based on whether heart or kidney dysfunction occurs first and the duration. The patient case involves a 55-year-old woman presenting with chest pain, shortness of breath, and leg swelling. Her labs show stage IV chronic kidney disease and elevated BNP. She likely has type 1 acute CRS, where acute heart failure led to acute kidney injury exacerbated by fluid overload.
Cardiorenal syndromes describe disorders where dysfunction in the heart and kidneys negatively impact one another. There are 5 subtypes based on etiology and chronicity. Type 1 involves acute kidney injury secondary to heart failure. Type 2 is chronic cardiac dysfunction causing chronic kidney disease. Type 3 is acute worsening of kidney function inducing heart issues. Type 4 is primary chronic kidney disease contributing to cardiac complications. Type 5 involves systemic conditions affecting both organs. Managing cardiorenal syndromes focuses on decongestion through diuresis while preventing worsening of renal function with neurohormonal blockade.
Acute kidney injury from diagnosis to prevention and treatment strategiesLeonardo Rodrigues
- Acute kidney injury (AKI) is characterized by a rapid decline in kidney function and is associated with increased short and long-term mortality. AKI diagnosis relies on changes in serum creatinine and urine output.
- Risk factors for AKI include older age, chronic kidney disease, comorbidities like diabetes and heart disease, as well as exposures to sepsis, surgery, nephrotoxins and shock. Causes of AKI include pre-renal, intrinsic renal and post-renal factors.
- Prevention strategies focus on identifying at-risk patients, optimizing volume status, and discontinuing or avoiding nephrotoxins. Treatment involves correcting hypovolemia, discontinuing
John B. Buse, MD, PhD; David Cherney, MD, PhD, FRCP(C); and Mikhail Kosiborod, MD, FACC, FAHA, prepared useful Practice Aids pertaining to SGLT2 inhibitors for this CME activity titled “Complex Cases in Contemporary Practice: Applying New Evidence for SGLT2 Inhibitors in the Management of Patients With Comorbid Cardiometabolic Diseases.” For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at https://bit.ly/3dFKZhs. CME credit will be available until July 22, 2021.
Guidelines for use of anticoagulant in ckd with atrial fibrillationNilesh Jadhav
1. Atrial fibrillation (AF) and chronic kidney disease (CKD) are bidirectionally linked, as CKD increases the risk of AF while AF increases the risk of CKD progression.
2. Patients with CKD and AF have an increased risk of stroke and thromboembolic events. They also exhibit a paradoxical increase in bleeding risk, especially those with severe CKD.
3. Non-vitamin K antagonist oral anticoagulants (NOACs) are preferred over warfarin for stroke prevention in patients with CKD and AF, as NOACs have more predictable anticoagulant effects than warfarin and are not associated with complications in CKD patients
A 33-year-old male smoker presented with abdominal pain, fatigue, nausea and dark urine. Laboratory tests showed acute kidney injury with a creatinine of 12.2 mg/dl. Abdominal ultrasound found enlarged kidneys with increased echogenicity. He was treated conservatively but his kidney function declined further. A renal biopsy was planned but his condition dramatically improved with corticosteroid treatment, suggesting acute interstitial nephritis.
UF vs diuretics in treatment of ADHF, Cardiorenal syndrome Mohamed E. Elrggal
1. Fluid overload and congestion are major characteristics of heart failure (HF) that are important treatment targets. Diuretics have limitations like resistance and worsening renal function.
2. Ultrafiltration (UF) theoretically has advantages over diuretics for acute decompensated heart failure (ADHF) by allowing faster fluid removal without electrolyte issues.
3. However, clinical trials have had conflicting results. The UNLOAD trial found greater benefits with UF, while the CARESS-HF trial found increased renal dysfunction and adverse events with UF.
4. Further research is needed to determine optimal patient selection, monitoring of plasma refill rate during UF, and long-term outcomes comparison
World Kidney Day was established to raise awareness of chronic kidney disease (CKD) and encourage detection and prevention programs. CKD affects over 20 million Americans and is a major cause of death worldwide. While kidney failure requiring dialysis has increased, CKD is often preventable or treatable through control of diabetes, hypertension, and obesity. World Kidney Day aims to educate the public and healthcare professionals about CKD risks and signs through collaborative events around the world each March.
1. Cardio-renal syndrome (CRS) describes conditions where acute or chronic dysfunction in one organ induces acute or chronic dysfunction in the other organ.
2. Management of CRS is challenging and involves diuretics, ACE inhibitors, beta blockers, and dialysis. However, treatment outcomes remain poor, with high mortality and rates of rehospitalization.
3. While advances have been made, CRS continues to significantly impact morbidity and mortality. Early multidisciplinary management may help improve outcomes, but effective new therapies are still needed to better treat and prevent this challenging condition.
This document summarizes the five types of cardiorenal syndromes (CRS). Type 1 is acute or chronic heart failure leading to kidney dysfunction. Type 2 is chronic kidney disease contributing to heart disease. Type 3 is acute kidney injury causing acute cardiac injury or dysfunction. Type 4 is chronic kidney disease causing chronic cardiac damage. Type 5 occurs when a systemic condition like sepsis or cirrhosis affects both the heart and kidneys. The document discusses the pathogenesis, risk factors, diagnosis and treatment approaches for each type of CRS.
This document discusses relative blood volume (RBV) monitoring and its potential applications in dialysis. It provides an overview of RBV monitoring principles, compartmental fluid shifts, and RBV profiles in relation to intradialytic hypotension. While RBV monitoring shows promise for fluid management and blood pressure control, evidence from studies is mixed. The largest study to date found RBV monitoring increased mortality and hospitalizations. Further research is still needed to fully understand the clinical utility and appropriate applications of RBV monitoring.
The document discusses renal failure and its relationship to cardiovascular disease. It provides statistics on the prevalence, incidence, and mortality rates of renal failure in the US and Australia. It then covers topics such as the structure and function of the kidneys, classification of renal failure, its effects on the cardiovascular system, and approaches to treatment including dialysis, transplantation, and their risks.
a-comprehensive-approach-to-kidney-disease-and-hypertension by HazwanMohd Hanafi
This document discusses kidney disease and hypertension. It begins by outlining the key functions of the kidneys, including regulating blood pressure through the renin-angiotensin-aldosterone system. It then examines the causes and classifications of acute and chronic kidney disease. Chronic kidney disease is a growing problem due to its asymptomatic nature in early stages. The document reviews factors that can damage the kidneys and lead to reduced glomerular filtration rate. It also discusses how chronic kidney disease and reduced kidney function are linked to increased risk of cardiovascular disease, anemia, and bone disease like renal osteodystrophy. Hypertension is both a common cause and complication of chronic kidney disease. Tight blood pressure control is important to slow
This document discusses anemia in patients with heart failure and kidney disease (cardiorenal anemia). It notes that anemia is common in these patients and associated with higher mortality and costs. The pathophysiology of cardiorenal disease and anemia are both multifactorial, involving interactions between cardiac function, renal dysfunction, inflammation, and other factors. The document outlines five subtypes of cardiorenal syndrome based on whether heart or kidney dysfunction is acute or chronic. It emphasizes that a multidisciplinary approach is needed to manage cardiorenal anemia given its complex causes.
Perioperative care of patients with kidney diseases prof (1). ahmed rabeeFarragBahbah
This document discusses perioperative care of patients with kidney disease. It covers preoperative assessment and investigations, renal risk assessment, surgical risks in chronic kidney disease (CKD) patients, and preventing acute kidney injury. Key points include performing a comprehensive evaluation of CKD patients' medical history and comorbidities; adjusting dosages of renally excreted drugs; optimizing fluid, electrolyte and acid-base balance; considering preoperative dialysis for volume overloaded patients; and involving nephrologists in care of transplant recipients. Emergent surgery and advanced CKD carry higher surgical risks. The goal is to identify and address risks to avoid worsening of renal function in the perioperative period.
The document discusses chronic kidney disease (CKD), including its definition, stages, diagnosis, prevalence, costs, and treatment options such as renal replacement therapy. CKD is common and often occurs alongside other conditions like cardiovascular disease or diabetes. While usually asymptomatic, CKD can be detected through simple tests and treating it can prevent progression and complications. However, it often goes unrecognized until later stages.
This document provides an overview of chronic kidney disease (CKD). It defines CKD as kidney damage or decreased kidney function lasting at least 3 months. The global prevalence of CKD is estimated to be 13.4% with higher rates in certain regions like eastern Uganda. Common causes include diabetes, hypertension, and glomerulonephritis. Later stages of CKD can cause complications like fluid overload, hyperkalemia, and metabolic acidosis which require management approaches like dietary modifications and medications. The document discusses evaluating and managing CKD and its associated risks and complications.
Chronic kidney disease (CKD) is a major public health problem worldwide. It is defined as kidney damage or decreased kidney function lasting at least 3 months. CKD is staged based on glomerular filtration rate and albuminuria levels, with stage 5 being kidney failure. Common causes include diabetes, hypertension, and glomerulonephritis. Management involves treating underlying causes, slowing progression, and treating complications like anemia, bone disease, and fluid overload.
Chronic kidney disease occurs when the kidneys are damaged and cannot effectively remove waste from the blood. It is usually caused by conditions that damage the kidneys such as high blood pressure, diabetes, and heart disease. While CKD has no cure, early treatment can slow its progression and prevent kidney failure. The document provides details on stages of CKD and codes for classifying and documenting CKD and related conditions.
This document discusses chronic kidney disease (CKD). It defines CKD as a progressive loss of renal function over months or years that is identified by increased creatinine levels and protein or blood in the urine. The two main causes of CKD are diabetes and high blood pressure, which together account for two-thirds of cases. Symptoms of CKD may not appear until later stages and include fatigue, poor appetite, and swollen limbs. Anyone can develop CKD, but those with diabetes, high blood pressure, family history, older age, or certain ethnicities are at higher risk. CKD is diagnosed through tests of kidney function and imaging and staged based on glomerular filtration rate.
Chronic kidney disease is defined by decreased kidney function or kidney damage lasting at least 3 months. It is caused by conditions that damage the kidneys such as diabetes and hypertension. Symptoms are often vague but can include fatigue, nausea, and decreased appetite. Complications include anemia, heart disease, bone disease, and nerve problems. Treatment focuses on controlling blood pressure and other risk factors as well as managing complications through diet, medication, dialysis or transplantation.
This document provides information on chronic kidney disease (CKD), including its definition, staging, etiology, pathogenesis, and management principles. CKD is defined as kidney damage or decreased kidney function persisting for at least 3 months. It is staged based on glomerular filtration rate (GFR) and the presence and severity of albuminuria. The pathogenesis involves both initiating factors that damage the kidneys as well as progressive mechanisms like compensatory hyperfiltration that eventually become maladaptive. Management focuses on identifying and treating the underlying cause, slowing progression, and treating complications through control of conditions like hypertension, anemia, and bone disease.
Chronic kidney disease (CKD) consists of a spectrum of different pathophysiologic processes associated with abnormal kidney function, and a progressive decline in glomerular filtration rate (GFR).
Cardio renal care-An integated best Practice Approchdrucsamal
This document provides information about a continuing medical education (CME) activity on cardio-renal syndromes (CRS). It begins with a declaration of disclosure stating the National Kidney Foundation's policy to ensure independence and manage any conflicts of interest among activity planners and faculty. The document then outlines the learning objectives, agenda, and pre-program questions. It also includes an overview of CRS, defining the different subtypes and discussing the bidirectional relationship between cardiac and renal dysfunction. Two case studies are presented to illustrate examples of acute cardiorenal syndrome type 1 and acute renocardiac syndrome type 3.
1. Chronic kidney disease (CKD) is defined as kidney damage or decreased kidney function lasting at least 3 months. It is staged based on glomerular filtration rate (GFR) from normal kidney function to kidney failure.
2. The most common causes of CKD are diabetes, hypertension, glomerulonephritis, and polycystic kidney disease. As CKD progresses, patients experience complications such as anemia, bone disease, cardiovascular disease, and metabolic acidosis.
3. Management of CKD focuses on slowing progression, treating complications, and preparing for renal replacement therapy if kidney failure occurs. Key interventions include blood pressure control, diabetes management, treatment of anemia, and dietary modifications.
This document discusses chronic kidney disease, which slowly damages the kidneys over months or years. The main causes are diabetes and high blood pressure. As the kidneys become less functional, waste builds up in the blood and the patient may experience symptoms like fatigue, nausea, and swelling. Tests can detect kidney damage and declining function. In the final stages, called end-stage renal disease, dialysis or transplant is needed to clean the blood. Home treatments focus on controlling blood pressure and blood sugar, healthy eating and exercise, and avoiding smoking.
This document discusses chronic kidney disease (CKD) in 3 sentences:
CKD is defined as kidney damage or decreased kidney function lasting over 3 months that leads to a progressive loss of kidney function and mass over time. CKD has many risk factors including diabetes, hypertension, family history, and is a global epidemic associated with high costs. The management of CKD focuses on monitoring kidney function, preventing progression, treating complications like anemia and bone disease, controlling cardiovascular risk factors, and preparing for renal replacement therapies like dialysis.
Chronic Kidney Disease Management and caresachintutor
Chronic kidney disease (CKD) is defined as the presence of kidney damage or an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 mt2, persisting for 3 months or more, irrespective of the cause.
Chronic kidney disease is a progressive loss of kidney function over months or years. It is defined as abnormalities in the kidney for 3 months with a glomerular filtration rate below 60. There are 5 stages based on GFR level with stage 5 being kidney failure requiring dialysis or transplant. Common causes are diabetes, hypertension, and glomerulonephritis. Symptoms vary but may include fatigue, skin changes, edema, and electrolyte imbalances. Diagnosis involves blood and urine tests to assess GFR and kidney damage markers. Treatment focuses on slowing progression through blood pressure control and managing complications.
This document discusses the diagnosis and management of acute kidney injury (AKI) in the intensive care unit (ICU). It defines AKI and outlines biomarkers that can help identify it earlier than creatinine. Common causes of AKI in the ICU include sepsis, major surgery, low cardiac output, and medications. The document reviews risk factors for developing AKI and strategies for preventing it, such as fluid management and avoiding nephrotoxins. It discusses general management of established AKI including nutrition, anticoagulation, and dialysis. The impact of renal replacement therapy on outcomes is also addressed.
An ensemble multi-model technique for predicting chronic kidney diseaseIJECEIAES
Chronic Kidney Disease (CKD) is a type of lifelong kidney disease that leads to the gradual loss of kidney function over time; the main function of the kidney is to filter the wastein the human body. When the kidney malfunctions, the wastes accumulate in our body leading to complete failure. Machine learning algorithms can be used in prediction of the kidney disease at early stages by analyzing the symptoms. The aim of this paper is to propose an ensemble learning technique for predicting Chronic Kidney Disease (CKD). We propose a new hybrid classifier called as ABC4.5, which is ensemble learning for predicting Chronic Kidney Disease (CKD). The proposed hybrid classifier is compared with the machine learning classifiers such as Support Vector Machine (SVM), Decision Tree (DT), C4.5, Particle Swarm Optimized Multi Layer Perceptron (PSO-MLP). The proposed classifier accurately predicts the occurrences of kidney disease by analysis various medical factors. The work comprises of two stages, the first stage consists of obtaining weak decision tree classifiers from C4.5 and in the second stage, the weak classifiers are added to the weighted sum to represent the final output for improved performance of the classifier.
Peripheral arterial disease is a complex disease affecting
the arterial system of the lower extremities. It has a
multifactorial etiology presenting with a wide spectrum
of symptoms. Clinical examination, laboratory
evaluation and imaging are essential for accurate
assessment of the severity of the disease. Treatment is
multidisciplinary comprising medical therapy as well as
surgical intervention. The article provides a systematic
approach to assessment and treatment of peripheral
arterial disease.
This document discusses cardiorenal syndrome (CRS), which occurs when acute or chronic dysfunction of the heart or kidneys induces dysfunction of the other organ. It defines five subtypes of CRS based on pathophysiology. Renal dysfunction is a strong predictor of mortality in heart failure patients. Biomarkers like NGAL and cystatin C can help detect acute kidney injury earlier than creatinine and predict outcomes. The interactions between the heart and kidneys involve pathways like the RAAS, inflammation, and oxidative stress.
Under Pressure : Kenneth Kruk's StrategyKenneth Kruk
Kenneth Kruk's story of transforming challenges into opportunities by leading successful medical record transitions and bridging scientific knowledge gaps during COVID-19.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
INFECTION OF THE BRAIN -ENCEPHALITIS ( PPT)blessyjannu21
Neurological system includes brain and spinal cord. It plays an important role in functioning of our body. Encephalitis is the inflammation of the brain. Causes include viral infections, infections from insect bites or an autoimmune reaction that affects the brain. It can be life-threatening or cause long-term complications. Treatment varies, but most people require hospitalization so they can receive intensive treatment, including life support.
Healthy Eating Habits:
Understanding Nutrition Labels: Teaches how to read and interpret food labels, focusing on serving sizes, calorie intake, and nutrients to limit or include.
Tips for Healthy Eating: Offers practical advice such as incorporating a variety of foods, practicing moderation, staying hydrated, and eating mindfully.
Benefits of Regular Exercise:
Physical Benefits: Discusses how exercise aids in weight management, muscle and bone health, cardiovascular health, and flexibility.
Mental Benefits: Explains the psychological advantages, including stress reduction, improved mood, and better sleep.
Tips for Staying Active:
Encourages consistency, variety in exercises, setting realistic goals, and finding enjoyable activities to maintain motivation.
Maintaining a Balanced Lifestyle:
Integrating Nutrition and Exercise: Suggests meal planning and incorporating physical activity into daily routines.
Monitoring Progress: Recommends tracking food intake and exercise, regular health check-ups, and provides tips for achieving balance, such as getting sufficient sleep, managing stress, and staying socially active.
We are one of the top Massage Spa Ajman Our highly skilled, experienced, and certified massage therapists from different corners of the world are committed to serving you with a soothing and relaxing experience. Luxuriate yourself at our spas in Sharjah and Ajman, which are indeed enriched with an ambiance of relaxation and tranquility. We could confidently claim that we are one of the most affordable Spa Ajman and Sharjah as well, where you can book the massage session of your choice for just 99 AED at any time as we are open 24 hours a day, 7 days a week.
Visit : https://massagespaajman.com/
Call : 052 987 1315
Can coffee help me lose weight? Yes, 25,422 users in the USA use it for that ...nirahealhty
The South Beach Coffee Java Diet is a variation of the popular South Beach Diet, which was developed by cardiologist Dr. Arthur Agatston. The original South Beach Diet focuses on consuming lean proteins, healthy fats, and low-glycemic index carbohydrates. The South Beach Coffee Java Diet adds the element of coffee, specifically caffeine, to enhance weight loss and improve energy levels.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Michigan HealthTech Market Map 2024. Includes 7 categories: Policy Makers, Academic Innovation Centers, Digital Health Providers, Healthcare Providers, Payers / Insurance, Device Companies, Life Science Companies, Innovation Accelerators. Developed by the Michigan-Israel Business Accelerator
Hypertension and it's role of physiotherapy in it.Vishal kr Thakur
This particular slides consist of- what is hypertension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is summary of hypertension -
Hypertension, also known as high blood pressure, is a serious medical condition that occurs when blood pressure in the body's arteries is consistently too high. Blood pressure is the force of blood pushing against the walls of blood vessels as the heart pumps it. Hypertension can increase the risk of heart disease, brain disease, kidney disease, and premature death.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)bkling
Your mindset is the way you make sense of the world around you. This lens influences the way you think, the way you feel, and how you might behave in certain situations. Let's talk about mindset myths that can get us into trouble and ways to cultivate a mindset to support your cancer survivorship in authentic ways. Let’s Talk About It!
This particular slides consist of- what is hypotension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is the summary of hypotension:
Hypotension, or low blood pressure, is when the pressure of blood circulating in the body is lower than normal or expected. It's only a problem if it negatively impacts the body and causes symptoms. Normal blood pressure is usually between 90/60 mmHg and 120/80 mmHg, but pressures below 90/60 are generally considered hypotensive.
1. 2516ALL0616-Q GNHJEKDEN
Chronic kidney disease (CKD) ICD-10-CM
Definition
Chronic kidney disease (chronic renal failure) is longstanding, progressive deterioration of renal function.
Background
The kidneys maintain health by removing wastes and fluid from the body. The kidneys also perform these other
important functions:
Regulate body water and other chemicals in the blood, such as sodium, potassium, phosphorus and calcium
Remove drugs and toxins
Release hormones into the blood to regulate blood pressure, make red blood cells and promote strong bones
Causes
The main causes of CKD are diabetes and high blood pressure. Other conditions that affect the kidneys include:
Glomerulonephritis (a group of diseases that
cause inflammation and damage to the glomeruli,
the filtering units of the kidney)
Inherited diseases, such as polycystic kidney
disease or sickle cell disease
Congenital malformations (present at birth)
Diseases of the immune system, such as lupus
Obstructions caused by problems such as kidney
stones, tumors or an enlarged prostate gland in
men
Repeated urinary tract infections
Lead poisoning
Long-term use of medicines that damage the
kidneys (for example, nonsteroidal anti-
inflammatory drugs [NSAIDs], such as ibuprofen
and naproxen)
Note: The cause is not always known.
Signs and symptoms
There may be no symptoms in the early stages of CKD. As kidney function decreases, symptoms may include:
Abnormal laboratory values (examples:
increased serum creatinine and blood urea
nitrogen [BUN]; or certain electrolytes)
High blood pressure that is difficult to control
Changes in urine output (example: urinating
less or more frequently than normal)
Swelling due to fluid build-up in the tissues
(edema)
Fatigue and weakness
Loss of appetite
Weight loss
Nausea and/or vomiting
Excessive sleepiness or inability to sleep
Headaches
Decreased mental sharpness, trouble
concentrating
Dry, itchy skin
Diagnostic tools
Laboratory testing to check kidney function (urinalysis, blood testing for creatinine, urea, electrolytes, etc.)
Glomerular filtration rate (GFR) − the best measure of the level of kidney function and determine the stage of
CKD
Imaging tests to evaluate for cause or type of CKD, including ultrasound, computed tomography (CT) scanning
and magnetic resonance imaging (MRI)
Renal biopsy (in some cases)
Treatment
Chronic kidney failure has no cure, but treatment can help control signs and symptoms, reduce complications and slow
the progress of the disease. The first priority is controlling the condition responsible for the kidney failure and its
complications (e.g., controlling diabetes or high blood pressure). Other treatments include:
Page 1 of4
Proper diet (protein management along with
salt, potassium and phosphorus restrictions
may help slow disease progression)
Daily exercise
Avoidance of dehydration
Avoidance of smoking and other tobacco
products
Avoidance of alcohol and illegal drugs
Avoidance of substances that are toxic to the
kidneys, such as NSAIDs
Treating complications (e.g., treatment of
anemia with erythropoietin to induce the
production of more red blood cells or
phosphate-binding medications to reduce the
amount of phosphate in the blood, which will
increase the amount of calcium available to the
bones)
2. Chronic kidney disease (CKD), continued ICD-10-CM
In end-stage kidney disease (when kidney function is reduced to 10-15 percent or less of capacity), conservative
measures as outlined above are no longer enough. Dialysis or kidney transplant become the only options to support life.
Documentation tips for providers
A good rule of thumb for any medical record is to limit – or avoid altogether – the use of acronyms and
abbreviations. While “CKD” is a commonly accepted medical abbreviation for chronic kidney disease, best practice is
as follows:
o The initial notation of an abbreviation or acronym should be spelled out in full with the acronym in
parentheses. For example: “Chronic kidney disease (CKD).”
o Subsequent mention of the condition can be made using the acronym.
o The diagnosis should be spelled out in full in the final impression or plan.
In the subjective section of the office note, document the presence or absence of any current symptoms related to
chronic kidney disease (e.g., fatigue, weakness, changes in urine output, etc.).
In the objective section of the office note, document:
o Any current associated physical exam findings (e.g., elevated blood pressure, edema, weight loss, etc.)
o Related diagnostic test results
o Presence of a surgically placed arteriovenous shunt for the purpose of dialysis, along with related exam
findings (e.g., date of placement, presence of a thrill or bruit)
Document details of current dialysis status (hemodialysis, peritoneal dialysis, frequency, etc.).
In the final assessment/impression:
o For a confirmed diagnosis of CKD, do not use descriptors that imply uncertainty (such as “probable,”
“apparently,” “likely” or “consistent with”).
o Document the specific stage of chronic kidney disease. Remember that medical coders are not allowed to
calculate the stage of CKD based on documentation of the glomerular filtration rate (GFR).
o Document the current status of CKD (stable, worsening, improved, etc.).
o State the cause of CKD, if known, using terms that clearly show cause-and-effect (such as “due to,”
“secondary to,” “related to,” etc.).
Document a specific and concise treatment plan for CKD.
o If referrals are made or consultations requested, the office note should indicate to whom or where the
referral or consultation is made or from whom consultation advice is requested.
o Document when you plan to see the patient again, even if only on an as-needed basis.
ICD-10-CM tips and resources for coders
CKD classifies to category N18. This category includes instructional notes that advise to code first any associated:
Diabetic chronic kidney disease (EØ8.22, EØ9.22, E1Ø.22, E11.22, E13.22)
Hypertensive chronic kidney disease (I12.-, I13.-)
Use an additional code to identify kidney transplant status, if applicable (Z94.Ø).
The ICD-10-CM manual classifies CKD based on the severity of the condition, designated by stages 1-5; the number of
each stage corresponds to the fourth character of the ICD-10-CM code. For example:
Page 2 of4
N18.2 (includes mild CKD)
CKD stage I N18.1
CKD stage II
CKD stageIII
CKD stageIV
CKD stage V
N18.3 (includes moderate CKD)
N18.4 (includes severe CKD)
N18.5
When the medical record does not document the stage of CKD, code N18.9 (chronic kidney disease, unspecified) is
assigned.
N18.9 includes all of the following:
Chronic renal disease
Chronic renal failure, not otherwise specified (NOS)
Chronic renal insufficiency
Chronic uremia
3. Chronic kidney disease (CKD), continued ICD-10-CM
Page 3 of4
End-stage renal disease (ESRD) classifies to code N18.6, which includes chronic kidney disease requiring chronic dialysis,
and advises to use an additional code to identify dialysis status (Z99.2). If both a stage of CKD and ESRD are
documented, assign only the code for ESRD (N18.6).
Dependence on renal dialysis codes to Z99.2, which includes:
Hemodialysis status
Peritoneal dialysisstatus
Presence of arteriovenous shunt (for dialysis)
Renal dialysis status NOS
Code Z99.2 excludes encounter for fitting and adjustment of dialysis catheter (Z49.Ø-) and noncompliance with renal
dialysis (Z91.15).
The National Kidney Foundation classifies the stages of CKD according to the patient’s glomerular filtration rate (GFR), a
diagnostic laboratory test that measures kidney function. GFR is calculated based on the patient’s age, race, gender,
height, weight and blood creatinine levels. However, as noted previously, coders cannot code the stage of CKD based on
documentation of the GFR value. Rather, the provider must document the stage of CKD.
Hypertensive chronic kidney disease
Assign codes from category I12, Hypertensive chronic kidney disease, when both hypertension and a condition
classifiable to category N18, Chronic kidney disease (CKD), are present. Unlike hypertension with heart disease, ICD-10-
CM presumes a cause-and-effect relationship and classifies chronic kidney disease with hypertension as hypertensive
chronic kidney disease.
The appropriate code from category N18 should be used as a secondary code with a code from category I12 to identify
the stage of chronic kidney disease:
I12.Ø Hypertensive chronic kidney disease with stage 5 CKD or end stage renal disease
I12.9 Hypertensive chronic kidney disease with stage 1 through stage 4 CKD, or unspecified CKD
Hypertensive heart and chronic kidney disease
Assign codes from combination category I13, Hypertensive heart and chronic kidney disease, when both hypertensive
kidney disease and hypertensive heart disease are stated in the diagnosis. Assume a relationship between the
hypertension and the chronic kidney disease, whether or not the condition is so designated. If heart failure is present,
assign an additional code from category I5Ø to identify the type of heart failure.
The appropriate code from category N18, Chronic kidney disease, should be used as a secondary code with a code from
category I13 to identify the stage of chronic kidney disease.
The codes in category I13 are combination codes that include hypertension, heart disease and chronic kidney disease.
The Includes note at I13 specifies that the conditions included at I11 and I12 are included together in I13. If a patient
has hypertension, heart disease and chronic kidney disease, a code from I13 should be used, not individual codes for
hypertension, heart disease and chronic kidney disease, or codes from I11 or I12.
4. Chronic kidney disease (CKD), continued
Page 4 of4
ICD-10-CM
Coding examples
Example 1
Final diagnosis Stage I chronic kidney disease,
worsening
ICD-10-CM
code(s) N18.1
Example 2
Final diagnosis Chronic kidney disease, stage III
with GFR 50
ICD-10-CM
code(s) N18.3
Example 3
Final diagnosis
End-stage renal disease, on
hemodialysis Tuesday, Thursday,
Saturday
ICD-10-CM
code(s) N18.6, Z99.2
Example 4
Final diagnosis Chronic renal insufficiency,
stable
ICD-10-CM
code(s)
N18.9
Example 6
Final diagnosis Chronic kidney disease, GFR 60
ICD-10-CM
code(s)
N18.9
Example 7
Final diagnosis Mild chronic kidney disease
ICD-10-CM
code(s)
N18.2
Example 8
Final diagnosis
Diabetes mellitus, hypertension
and chronic kidney disease stage
IV
ICD-10-CM
code(s) E11.9, I12.9, N18.4
Rationale
Diabetes mellitus is not linked to
chronic kidney disease. ICD-10-
CM presumes a cause-and-
effect relationship between
chronic kidney disease and
hypertension.
Example 5
Final diagnosis
Chronic kidney disease stage II
secondary to diabetes mellitus
and hypertension
ICD-10-CM
code(s) E11.22, I12.9, N18.2
Rationale
Diabetes mellitus and
hypertension are linked in a
cause-and-effect relationship to
chronic kidney disease.
Example 9
Final diagnosis
Hypertensive heart disease with
chronic kidney disease stage IV
and congestive heart failure
ICD-10-CM
code(s) I13.Ø, I5Ø.9, N18.4
References: American Hospital Association Coding Clinic; ICD-10-CM Official Guidelines and Reporting; Mayo Clinic;
Merck Manual; National Kidney Foundation; WebMD